• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: MEDTRONIC IRELAND VALIANT CAPTIVIA - FF; SYSTEM, ENDOVASCULAR GRAFT, AORTIC ANEURYSM TREATMENT

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

MEDTRONIC IRELAND VALIANT CAPTIVIA - FF; SYSTEM, ENDOVASCULAR GRAFT, AORTIC ANEURYSM TREATMENT Back to Search Results
Model Number VAMF3636C150TU
Medical Device Problem Code Leak/Splash (1354)
Health Effect - Clinical Codes No Consequences Or Impact To Patient (2199); Injury (2348)
Date of Event 05/08/2019
Type of Reportable Event Serious Injury
Additional Manufacturer Narrative
If information is provided in the future, a supplemental report will be issued.
 
Event or Problem Description
A valiant captivia stent graft system was implanted in a patient for the endovascular treatment of an unknown diameter thoracic aortic aneurysm.It was reported that approximately 2 years 8 months post index procedure, a follow up ct showed a type ia endoleak.Per the physician, the cause of the event could not be determined.No additional clinical sequelae were reported and the patient is fine.
 
Additional Manufacturer Narrative
Additional information received: a re-intervention procedure was carried completed.An arch debranching and extension of the graft proximally into the healthy ascending aorta was carried out.There was no type ia endoleak at the end of the procedure.Film evaluation summary: conclusions: the reported proximal type i endoleak was confirmed; however, the exact cause could not be determined from the films provided.The anatomy at implant is unknown and earlier post-implant films were not available for review and comparison.There currently appears to be a marginal proximal seal with insufficient radial oversizing, which most likely has led to the type ia endoleak.It is possible that disease progression (thoracic vessel dilation) may have contributed to the likely proximal type i endoleak.If information is provided in the future, a supplemental report will be issued.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
VALIANT CAPTIVIA - FF
Common Device Name
SYSTEM, ENDOVASCULAR GRAFT, AORTIC ANEURYSM TREATMENT
Manufacturer (Section D)
MEDTRONIC IRELAND
parkmore business park west
galway
MDR Report Key8627452
Report Number9612164-2019-01857
Device Sequence Number19324980
Product Code MIH
UDI-Device Identifier00643169346963
UDI-Public00643169346963
Combination Product (Y/N)N
Initial Reporter StateTX
Initial Reporter CountryUS
PMA/510(K) Number
P100040
Number of Events Summarized1
Summary Report (Y/N)N
Device Implanted Year2016
Reporter Type Manufacturer
Report Source company representative,health
Initial Reporter Occupation Physician
Type of Report Initial,Followup
Report Date (Section B) 06/12/2019
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? Yes
Operator of Device Health Professional
Device Expiration Date06/28/2018
Device Model NumberVAMF3636C150TU
Device Catalogue NumberVAMF3636C150TU
Was Device Available for Evaluation? Device Returned to Manufacturer
Date Returned to Manufacturer05/13/2019
Initial Date Received by Manufacturer 05/09/2019
Supplement Date Received by Manufacturer05/21/2019
Initial Report FDA Received Date05/21/2019
Supplement Report FDA Received Date06/12/2019
Is This a Single-Use Device that was
Reprocessed and Reused on a Patient? (Y/N)
No
Patient Sequence Number1
Outcome Attributed to Adverse Event Required Intervention;
Patient Age66 YR
-
-